Investigating the effect of spirulina algae in type 2 diabetes

Investigating the effect of sauce prepared with spirulina algae on anthropometric indicators, glycemic markers, lipid profile, malondialdehyde and appetite in patients with type 2 diabetes: a double-blind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191126045515N1

Enrollment

Registered

2020-07-18

Start date

2019-12-31

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: The group receiving the spirulina algae sauce would use the sauce containing 2 grams of Spirulina per day up to 2 months. The products were produced in Tiondasht Ke

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes (doctor's diagnosis) Fasting blood sugar higher than 130 Not using insulin Age between 30 and 60 years

Exclusion criteria

Exclusion criteria: Suffering from cardiovascular, liver, kidney and thyroid disorders Specific medical conditions that require specific diet and exercise changes Participate in other studies over the past 6 months Use any supplements or specific diets Pregnancy and lactation Alcohol consumption and smoking

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Before and after intervention. Method of measurement: By the means of Pars Azmoon Company kit and auto analyzer.;Insulin. Timepoint: Before and after intervention. Method of measurement: By Diameter Company Kit.;Hemoglobin A1c. Timepoint: Before and after intervention. Method of measurement: By diazyme kit.;Insulin resistance. Timepoint: Before and after intervention. Method of measurement: With Homeostatic Model Assessment for Insulin Resistance index and formula.;Appetite. Timepoint: Before and after intervention. Method of measurement: With Visual analogue scales questionnaire.;Serum lipid profile. Timepoint: Before and after intervention. Method of measurement: By the means of Pars Azmoon Company kit and auto analyzer.;Malondialdehyde. Timepoint: Before and after intervention. Method of measurement: Thiobarbituric acid method.;Weight. Timepoint: Before and after intervention. Method of measurement: Digital scales.;Body composition. Timepoint: Before and after the intervention. Method of measurement: Bioelectric impedance analysis.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before and after intervention. Method of measurement: By the means of Pars Azmoon Company kit and auto analyzer.;Insulin. Timepoint: Before and after intervention. Method of measurement: By Diameter Company Kit.;Hemoglobin A1c. Timepoint: Before and after intervention. Method of measurement: By diazyme kit.;Insulin resistance. Timepoint: Before and after intervention. Method of measurement: With Homeostatic Model Assessment for Insulin Resistance index and formula.;Appetite. Timepoint: Before and after intervention. Method of measurement: With Visual analogue scales questionnaire.;Serum lipid profile. Timepoint: Before and after intervention. Method of measurement: By the means of Pars Azmoon Company kit and auto analyzer.;Malondialdehyde. Timepoint: Before and after intervention. Method of measurement: Thiobarbituric acid method.;Weight. Timepoint: Before and after intervention. Method of measurement: Digital scales.;Body composition. Timepoint: Before and after the intervention. Method of measurement: Bioelectric impedance analysis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Rezaiyan

Shiraz University of Medical Sciences

mrezaiyan0@gmail.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026